drugset / Trial / NCT04984512
The Efficacy And Safety Of Mitizodone Phosphate Tablets In The Treatment of Patient With Major Depressive Disorder
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a phase 2 and 3 adaptive design study for Mitizodone Phosphate,to find out an optimal dose in phase 2 period and confirm the result an efficacy and safety in phase 3 period.Dose-finding will be done after 8 weeks of double-blinded treatment in phase 2 period and will be assessed by both efficacy and safety from 3 dose groups of Mitizodone Phosphate.The dose be found in phase 2 period will be evaluated on efficacy and safety when compared with placebo in phase 3 period with a duration of 8 weeks treatment.The target subjects are patients with MDD.
Timeline
- Start
- 2021-12-14
- Primary completion
- 2027-07
- Completion
- 2027-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mitizodone | Unknown | 10 mg | Oral |
| Subject | Mitizodone | Unknown | 20 mg | Oral |
| Subject | Mitizodone | Unknown | 40 mg | Oral |